Overview
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. It is a pioneer in personalized healthcare and want to further transform how healthcare
...
Read More is delivered to have an even greater impact. To provide the best care for each person it partners with many stakeholders and combine its strengths in Diagnostics and Pharma with data insights from the clinical practice. The company markets many of its bestsellers through California-based subsidiary Genentech and Japanese affiliate Chugai Pharmaceutical. Roche generates the majority of its revenue in North America.
Read Less
Read More is delivered to have an even greater impact. To provide the best care for each person it partners with many stakeholders and combine its strengths in Diagnostics and Pharma with data insights from the clinical practice. The company markets many of its bestsellers through California-based subsidiary Genentech and Japanese affiliate Chugai Pharmaceutical. Roche generates the majority of its revenue in North America.
Read Less
Severin Schwan
See more contacts
Nondepository Credit Intermediation
,
Credit Intermediation and Related Activities
,
Finance and Insurance
,
Intermediate investment banks
Activities Related to Credit Intermediation
,
Agencies, Brokerages, and Other Insurance Related Activities
,
Depository Credit Intermediation
,
Insurance Carriers
,
Insurance and Employee Benefit Funds
,
Monetary Authorities-Central Bank
,
Other Financial Investment Activities
,
Other Investment Pools and Funds
View more , Securities and Commodity Contracts Intermediation and Brokerage Securities and Commodity Exchanges
View fewer
View more , Securities and Commodity Contracts Intermediation and Brokerage Securities and Commodity Exchanges
View fewer
?
?
Actual
$70.85 billion
Actual
3.23%
-28.01%
$101,801
DEC
?
?
Swiss:ROG
Contacts
Get in Touch with 24 Principals*
-
Severin SchwanChairman of the Board and Authorised Signatory
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$70.85 billion
USD
Actual
1 USD = 0.8807 CHF
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $22,816 | $18,275 | $20,215 |
| Net Investing Cash | -$12,936 | -$12,085 | -$3,320 |
| Net Financing Cash | -$7,743 | -$4,813 | -$18,480 |
| Net Change in Cash | $2,137 | $1,377 | -$1,585 |
| Cash at Beginning of Period | $6,104 | $5,667 | $7,778 |
| Cash at End of Period | $7,920 | $6,104 | $5,667 |
| Capital Expenditure | -$5,688 | -$5,279 | -$5,169 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $7,920 | $6,104 | $5,667 |
| Accounts Receivable | $13,631 | $13,212 | $13,765 |
| Inventories | $8,636 | $8,799 | $9,771 |
| Other Current Assets | $15,272 | $9,862 | $9,194 |
| Asset Summary | |||
| Total Current Assets | $45,460 | $37,977 | $38,397 |
| Tangible Fixed Assets | $26,956 | $26,047 | $27,488 |
| Intangible Assets | $19,647 | $16,837 | $10,997 |
| Total Assets | $101,801 | $90,468 | $88,151 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $4,524 | $4,001 | $4,384 |
| Short-Term Debt | $4,465 | $4,995 | $4,496 |
| Other Current Liabilities | $21,695 | $19,191 | $22,049 |
| Liability Summary | |||
| Total Current Liabilities | $30,684 | $28,187 | $30,929 |
| Long-Term Debt | $34,884 | $28,171 | $24,289 |
| Other Long-Term Liabilities | $77 | $35 | $50 |
| Total Liabilities | $74,532 | $64,955 | $63,741 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $121 | $121 | $121 |
| Retained Earnings | $49,781 | $48,084 | $44,212 |
| Equity Summary | |||
| Total Equity | $36,071 | $33,286 | $31,784 |
| Shares Outstanding | 795,400,695 | 797,241,945 | 799,180,671 |